文献速递头颈外科

美国喉癌发病率与死亡率趋势

Trends in Incidence and Mortality of Larynx Cancer in the US.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2023-01-01

该队列研究基于美国监测、流行病学和最终结果(SEER)数据库1986年至2018年40 850例喉癌患者,分析发病率与死亡率趋势。结果显示喉癌发病率下降55%,而死亡率仅下降43%,相对病死率上升25%,局部病变发病率下降是发病率下降的主要原因。

要点

  • 喉癌发病率从5.00/10万降至2.26/10万,下降55%。
  • 死亡率从1.59/10万降至0.89/10万,仅下降43%。
  • 相对病死率上升25%,局部病变发病率下降40%至45%。

核心结论

  • 1986年至2018年美国喉癌发病率下降,主要因局部病变发病率下降;死亡率未同步下降,总体病死率相对增加25%。

研究设计与样本

  • 队列研究,使用美国监测、流行病学和最终结果(SEER)项目数据库,纳入1986年1月1日至2018年12月31日诊断为喉癌的18岁以上患者40 850例(80.4%为男性)。

主要发现

  • 发病率从5.00/10万(95%CI 4.70-5.32)降至2.26/10万(95%CI 2.11-2.42),下降55%。
  • 死亡率从1.59/10万(95%CI 1.53-1.64)降至0.89/10万(95%CI 0.86-0.92),下降43%。
  • 相对病死率增加25%。
  • 局部病变发病率1986年至2002年从2.65/10万(95%CI 2.44-2.89)降至1.60/10万(95%CI 1.45-1.76),下降40%;2005年至2018年从2.15/10万(95%CI 1.98-2.34)降至1.19/10万(95%CI 1.08-1.31),下降45%。
  • 喉癌亚部位分布保持稳定,多数病例累及声门;无论分期,接受手术作为首次治疗的患者比例下降。

临床怎么用

  • 作者认为,鼓励因癌症疑虑更早转诊、将资源集中于喉癌发病率仍最高的地区、重新关注不同肿瘤生物学特征的新生物学原因研究以及开展直接比较治疗的试验,可能有助于扭转这一趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Larynx cancer is associated with considerable morbidity for patients and has a high mortality rate. Historical analyses showed that the incidence of larynx cancer was decreasing but the mortality was not similarly improving. OBJECTIVE: To assess whether incidence and mortality trends in larynx cancer in the US have improved. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used population-based data from the Surveillance, Epidemiology, and End Results Program database for patients older than 18 years who were diagnosed with laryngeal cancer between January 1, 1986, and December 31, 2018. Data were analyzed from May 1, 2021, to May 31, 2022. MAIN OUTCOMES AND MEASURES: The main outcomes were incidence and mortality of larynx cancer by sex, subsite, and patterns of surgical treatment. RESULTS: Among 40 850 US patients with larynx cancer diagnosed from 1986 to 2018 (80.4% male), the incidence of larynx cancer decreased 55% from 5.00 per 100 000 people (95% CI, 4.70-5.32 per 100 000 people) to 2.26 per 100 000 people (95% CI, 2.11-2.42 per 100 000 people). During the same period, mortality decreased only 43% from 1.59 per 100 000 people (95% CI, 1.53-1.64 per 100 000 people) to 0.89 per 100 000 people (95% CI, 0.86-0.92 per 100 000 people). This corresponds to a 25% relative increase in case-fatality rate. Examination by stage showed a decrease in the incidence of localized disease at diagnosis of 40% from 2.65 per 100 000 people (95% CI, 2.44-2.89 per 100 000 people) to 1.60 per 100 000 people (95% CI, 1.45-1.76 per 100 000 people) from 1986 to 2002 and of 45% from 2.15 per 100 000 people (95% CI, 1.98-2.34 per 100 000 people) to 1.19 per 100 000 people (95% CI, 1.08-1.31 per 100 000 people) from 2005 to 2018. Distribution of larynx cancer by subsite remained stable, with most cases affecting the glottis. The proportion of patients receiving surgery as their first course of treatment decreased regardless of stage at presentation. CONCLUSIONS AND RELEVANCE: In this cohort study, between 1986 and 2018, the incidence of larynx cancer decreased in the US, primarily because of the decrease in the incidence of localized disease. Mortality did not decrease similarly, resulting in an increased case-fatality rate overall. Encouraging earlier referrals for cancer concern, focusing resources where larynx cancer rates remain highest, renewing attention to research on new biologic causes of different tumor biologic characteristics, and conducting trials to directly compare treatments may help reverse this trend.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Divakar P, Davies L. Trends in Incidence and Mortality of Larynx Cancer in the US. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 36394832. doi:10.1001/jamaoto.2022.3636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。